Skip to main content


Nucala® (mepolizumab) is now listed on the PBS - 3 April 2023

Nucala® (mepolizumab) is now listed on the pharmaceutical benefits scheme (PBS) for Australians with chronic rhinosinusitis with nasal polyps.

As the first biologic treatment to be PBS-subsidised for the treatment of severe chronic rhinosinusitis with nasal polyps, the availability of Nucala on the PBS provides Australians living with this chronic condition affordable access to a treatment that may help to effectively improve their health and wellbeing and reduce the burden of disease.

Speak to your GP to discuss the appropriate management of your condition and for referral to a specialist when needed.


If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.